Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
NCT ID: NCT00292526
Last Updated: 2017-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
114 participants
INTERVENTIONAL
2000-11-30
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation and Management of Cardio Toxicity in Oncologic Patients
NCT02818517
Prevention of Anthracycline-induced Cardiotoxicity
NCT01968200
Enalapril After Anthracycline Cardiotoxicity
NCT00000547
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
NCT01212926
Detection of Chemotherapy Induced Cardiotoxicity
NCT00636844
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
enalapril arm
treatment with enalapril
Enalapril
enalapril orally administered
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enalapril
enalapril orally administered
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Institute of Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carlo M Cipolla, MD
Role: STUDY_DIRECTOR
European Institute of Oncology
Daniela Cardinale, MD
Role: PRINCIPAL_INVESTIGATOR
European Institute of Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
European Institute of Oncology
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004 Jun 8;109(22):2749-54. doi: 10.1161/01.CIR.0000130926.51766.CC. Epub 2004 May 17.
Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000 Aug;36(2):517-22. doi: 10.1016/s0735-1097(00)00748-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IEO S67/500
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.